Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 11/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10091005 | 0.96 | CNR2 (0.47) | CNR2KCNK3PDE4APDE4BPDE4C | |
| SCHEMBL10091052 | 0.92 | CNR2 (0.53) | CNR2KCNK3GRM2CNR1 | |
| SCHEMBL10091068 | 0.91 | CNR2 (0.44) | CNR2KCNK3GRM2CNR1 | |
| SCHEMBL10091066 | 0.90 | CNR2 (0.45) | CNR2KCNK3GRM2 | |
| SCHEMBL10091070 | 0.90 | CNR2 (0.43) | CNR2KCNK3GRM2CNR1 | |
| SCHEMBL10091069 | 0.89 | CNR2 (0.42) | CNR2KCNK3GRM2PDE4APDE4B | |
| SCHEMBL342271 | 0.89 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL342270 | 0.89 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL10091059 | 0.88 | CNR2 (0.42) | CNR2KCNK3GRM2CNR1 | |
| SCHEMBL10091010 | 0.88 | CNR2 (0.47) | CNR2KCNK3GRM2PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835422-B2 | Substituted imidazoheterocycle derivatives | CARA THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835422-B2 | Substituted imidazoheterocycle derivatives | CARA THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CARA THERAPEUTICS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CARA THERAPEUTICS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CNR1, CNR2, HRH1 | CNR2 2/4885KCNK3 1442/4885GRM2 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.